美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Alamar Biosciences, Inc.

27.89

+0.12000.43%

盤後：27.890.00000.00%16:10 EDT

成交量：32.39萬

成交額：904.78萬

市值：19.33億

市盈率：-38.95

高：30.62

開：28.30

低：27.41

收：27.77

52周最高：38.54

52周最低：18.85

股本：6,931.12萬

流通股本：1,293.75萬

量比：1.48

換手率：2.50%

股息：- -

股息率：- -

每股收益(TTM):-0.7160

每股收益(LYR):-2.5873

淨資產收益率：-33.57%

總資產收益率：-13.53%

市淨率：6.18

市盈率(LYR):-10.78

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

Alamar Biosciences攜手阿爾茨海默病數據倡議與Gates Ventures，深化全球合作

財報前瞻｜Alamar Biosciences, Inc.本季度營收預計約2,593.98萬美元，機構觀點偏看多

高盛系免疫療法新鋭Attovia(ATTO.US)衝刺納斯達克：最高募資2.125億美元，成生物科技IPO熱潮最新註腳

Alzpath 擴大與 Alamar Biosciences 的戰略合作，推動阿爾茨海默病臨床診斷進步

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/ALMR"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ALMR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMR\",,,,,undefined,":{"symbol":"ALMR","market":"US","secType":"STK","nameCN":"Alamar Biosciences, Inc.","latestPrice":27.89,"timestamp":1789156800000,"preClose":27.77,"halted":0,"volume":323878,"hourTrading":{"tag":"盘后","latestPrice":27.89,"preClose":27.89,"latestTime":"16:10 EDT","volume":2251,"amount":62780.39,"timestamp":1789157405041,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0043212099387828955,"floatShares":12937500,"shares":69311200,"eps":-0.716,"marketStatus":"休市中","change":0.12,"latestTime":"09-11 16:00:00 EDT","open":28.3,"high":30.6198,"low":27.41,"amount":9047802,"amplitude":0.115585,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.716,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":27.77,"preHourTrading":{"tag":"盘前","latestPrice":29.14,"preClose":27.77,"latestTime":"09:25 EDT","volume":50,"amount":1421.12,"timestamp":1789133100028,"change":1.37,"changeRate":0.049334,"amplitude":0.049694},"postHourTrading":{"tag":"盘后","latestPrice":27.89,"preClose":27.89,"latestTime":"16:10 EDT","volume":2251,"amount":62780.39,"timestamp":1789157405041,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.4757991689924421},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMR\",,,,,undefined,":{"symbol":"ALMR","floatShares":12937500,"roa":"-13.53%","roe":"-33.57%","lyrEps":-2.587299,"volumeRatio":1.4757991689924421,"shares":69311200,"dividePrice":0,"high":30.6198,"amplitude":0.115585,"preClose":27.77,"low":27.41,"week52Low":18.845,"pbRate":"6.18","psRate":"19.25","week52High":38.54,"institutionHeld":0,"latestPrice":27.89,"eps":-0.716,"divideRate":0,"volume":323878,"delay":0,"ttmEps":-0.716,"open":28.3,"prevYearClose":17,"prevWeekClose":30.8,"prevMonthClose":30.54,"prevQuarterClose":27.09,"fiveDayClose":30.57,"twentyDayClose":32.92,"sixtyDayClose":20.06},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALMR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-10","symbol":"ALMR","fiscalQuarterEnding":"2026/06","expectedEps":-0.36,"name":null,"time":"盤後","type":"earning","dateTimestamp":1786334400000,"reportTimeType":"post","actualEps":-0.22}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALMR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALMR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.4,"hold":0.2,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4,"analysts":5,"updateTime":1779249600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ALMR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ALMR","date":"2026-09-11","current":-38.952514,"percent":0.691489,"low":-61.051551,"twenty":-46.592546,"median":-41.648874,"eighty":-34.323263,"high":-30.427746,"avg":-42.096563,"sd":7.586742,"marketCap":1927037111},"quantilePoints":[{"date":"2026-05-01","current":-57.277289,"twenty":-59.990183,"median":-57.277289,"eighty":-56.655108,"marketCap":1707951482},{"date":"2026-05-08","current":-54.120633,"twenty":-59.175857,"median":-56.408065,"eighty":-54.495772,"marketCap":1613823165},{"date":"2026-05-15","current":-35.878919,"twenty":-57.629553,"median":-54.669617,"eighty":-53.99338,"marketCap":1560194796},{"date":"2026-05-22","current":-35.066025,"twenty":-56.9113,"median":-54.440874,"eighty":-34.919385,"marketCap":1524846092},{"date":"2026-05-29","current":-31.495666,"twenty":-56.325717,"median":-53.802501,"eighty":-32.467951,"marketCap":1369589035},{"date":"2026-06-05","current":-34.253131,"twenty":-55.282649,"median":-35.878919,"eighty":-32.646469,"marketCap":1489497387},{"date":"2026-06-12","current":-35.368868,"twenty":-54.724515,"median":-34.699426,"eighty":-32.401007,"marketCap":1538015217},{"date":"2026-06-18","current":-32.196986,"twenty":-54.651317,"median":-34.308917,"eighty":-32.158732,"marketCap":1400085957},{"date":"2026-06-26","current":-42.828368,"twenty":-54.587269,"median":-35.066025,"eighty":-32.350002,"marketCap":1862391567},{"date":"2026-07-02","current":-41.648874,"twenty":-54.495772,"median":-35.368868,"eighty":-32.60184,"marketCap":1811101290},{"date":"2026-07-10","current":-42.206743,"twenty":-54.303628,"median":-36.436788,"eighty":-32.691099,"marketCap":1835360205},{"date":"2026-07-17","current":-39.76806,"twenty":-53.99338,"median":-39.098618,"eighty":-32.700662,"marketCap":1729314090},{"date":"2026-07-24","current":-41.266336,"twenty":-53.295956,"median":-39.903543,"eighty":-32.786733,"marketCap":1794466605},{"date":"2026-07-31","current":-39.959329,"twenty":-52.542305,"median":-39.576791,"eighty":-32.978002,"marketCap":1737631433},{"date":"2026-08-07","current":-44.788877,"twenty":-45.298929,"median":-40.039025,"eighty":-33.153333,"marketCap":1947644326},{"date":"2026-08-14","current":-46.000078,"twenty":-46.279543,"median":-40.206385,"eighty":-33.248967,"marketCap":2284409856},{"date":"2026-08-21","current":-48.403484,"twenty":-48.403484,"median":-40.899736,"eighty":-33.37648,"marketCap":2403765414},{"date":"2026-08-28","current":-46.111864,"twenty":-47.844552,"median":-41.354,"eighty":-34.253131,"marketCap":2289961278},{"date":"2026-09-04","current":-42.716354,"twenty":-47.62098,"median":-41.648874,"eighty":-34.285009,"marketCap":2121336856},{"date":"2026-09-11","current":-38.803832,"twenty":-46.592546,"median":-41.648874,"eighty":-34.323263,"marketCap":1927037111}],"updateTime":1789302068307},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALMR\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1165363440","title":"Alamar Biosciences攜手阿爾茨海默病數據倡議與Gates Ventures，深化全球合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1165363440","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165363440?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 04:05","pubTimestamp":1786392312,"startTime":"0","endTime":"0","summary":"Alamar Biosciences（简称：ALMR）正积极拓展其全球战略版图，与阿尔茨海默病数据倡议（Alzheimer’s Disease Data Initiative）以及Gates Ventures达成更广泛的合作伙伴关系。这一举措，旨在通过数据共享与技术协同，加速对阿尔茨海默病的研究与疗法开发。合作方将整合各自资源，推动全球范围内的疾病数据整合与创新诊断工具的应用。Alamar Biosciences的管理层表示，此合作将进一步提升其平台在神经退行性疾病领域的应用潜力，为患者群体带来更精准的诊断方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130899284","title":"財報前瞻｜Alamar Biosciences, Inc.本季度營收預計約2,593.98萬美元，機構觀點偏看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1130899284","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130899284?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 08:55","pubTimestamp":1785718537,"startTime":"0","endTime":"0","summary":"Alamar Biosciences, Inc.将于2026年08月10日盘后发布2026年第二季度财报，市场聚焦收入延续性与亏损收窄节奏。市场一致预期显示，本季度Alamar Biosciences, Inc.营收预计为2,593.98万美元，同比增速记录为0.00%；调整后每股收益预计为—0.33美元，同比增速记录为0.00%，公司层面暂未披露本季度的毛利率与净利率指引，亦未提供本季度收入指引。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Alamar Biosciences, Inc.本季度营收预计约2,593.98万美元，机构观点偏看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655844683","title":"高盛系免疫療法新鋭Attovia(ATTO.US)衝刺納斯達克：最高募資2.125億美元，成生物科技IPO熱潮最新註腳","url":"https://stock-news.laohu8.com/highlight/detail?id=2655844683","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655844683?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 11:39","pubTimestamp":1785382784,"startTime":"0","endTime":"0","summary":"发行概览：从1亿美元到2.125亿美元，需求推动规模扩大Attovia于7月14日首次提交IPO申请时，计划募资约1亿美元。以区间中点计算，Attovia的完全稀释市值约为6.49亿美元。截至2026年3月31日，公司累计融资达2.558亿美元。Alamar至今仍是Attovia的重要股东。市场背景：生物科技IPO的“黄金窗口”Attovia选择此时上市绝非偶然——2026年正成为生物科技IPO的“大年”。至少还有六家生物科技公司已在7月提交IPO申请，预计将在夏末前完成定价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4552","LU2237443549.SGD","LU2237438978.USD","LU1668664300.SGD","LU1894683348.USD","LU2237443622.USD","LU2471134796.USD","BK4226","IE0002270589.USD","ATTO","LU1868837300.USD","LU0251131958.USD","LU2237443895.HKD","IE00B19Z3B42.SGD","IE00BFXG1179.USD","LU1868836757.USD","GS","GSX","BK4121","IE0004091025.USD","LU0096364046.USD","LU0868494708.USD","LU2471134879.HKD","IE00BSNM7G36.USD","LU2265009873.SGD","LU2237443978.SGD","LU0345770993.USD","BK4550","ALMR","LU0868494617.USD","LU0942090050.USD","IE0034235188.USD","LU0061475181.USD","LU1804176565.USD","BK4588","LU1791807156.HKD","LU2471134952.CNY","IE00B19Z3581.USD","BK4585","LU1868836591.USD","LU1894683264.USD","LU0106831901.USD","LU2750360997.AUD","LU2237443382.USD","LU0048573561.USD","BK4504","LU2237443465.HKD","BK4533","BK4516","LU0251142724.SGD","BK4143","LU0742534661.SGD","LU1868836914.USD","LU2471134523.USD","LU1868837136.USD","LU0345770308.USD","IE0004086264.USD","LU2750360641.GBP","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120675244","title":"Alzpath 擴大與 Alamar Biosciences 的戰略合作，推動阿爾茨海默病臨床診斷進步","url":"https://stock-news.laohu8.com/highlight/detail?id=1120675244","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120675244?lang=zh_tw&edition=fundamental","pubTime":"2026-07-23 20:35","pubTimestamp":1784810143,"startTime":"0","endTime":"0","summary":"Alzpath 宣布，已进一步扩展与 Alamar Biosciences 的战略合作协议。双方旨在携手推进阿尔茨海默病的临床诊断技术。通过此次深化合作，Alzpath 将充分利用 Alamar Biosciences 的创新平台，加速相关诊断工具的开发与应用。这一举措有望为阿尔茨海默病的早期检测与精准诊断带来显著突破，从而更好地满足患者和医疗系统的迫切需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMR","BK4121"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ALMR\",params:#limit:6,delay:false,,,undefined,":[]}}